A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies
Latest Information Update: 30 Apr 2024
At a glance
- Drugs Cabotamig (Primary) ; Atezolizumab
- Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Intestinal cancer; Liver cancer; Pancreatic cancer
- Focus Adverse reactions; First in man
- Sponsors Arbele
Most Recent Events
- 26 Apr 2024 According to an Arbele media release, the company announced the positive recommendation from the second meeting of the Data Monitoring Committee (DMC) to continue the A001 Phase I clinical trial evaluating cabotamig (ARB202) in patients with advanced gastrointestinal (GI) cancers without modification to the trial protocol.
- 02 Aug 2023 According to an Arbele media release, As of 29 Jun 2023, the safety review committee and an independent data monitoring committee, DMC, had approved the trial to continue without modification. The company has completed dosing across the first 3 dose-level cohorts ranging from 0.0003 to 0.003 mg/kg by single IV doses.
- 02 Aug 2023 Results presented in an Arbele Media Release